Center-Authored Papers

Filters: Author is Othus, M  [Clear All Filters]
Journal Article
Othus M, Bansal A, Koepl L, Wagner S, Ramsey S.  2017.  Accounting for Cured Patients in Cost-Effectiveness Analysis.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20(4):705-709. Abstract
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N et al..  2014.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.. The lancet oncology. 15(9):986-96. Abstract
Carson WE, Unger JM, Sosman JA, Flaherty LE, Tuthill R, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A et al..  2014.  Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-negative Melanoma: Long-Term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival.. Cancer immunology research. Abstract
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.  2015.  Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK et al..  2014.  Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.. British journal of haematology. Abstract
Korn EL, Othus M, Chen T, Freidlin B.  2017.  Assessing treatment efficacy in the subset of responders in a randomized clinical trial.. Annals of oncology : official journal of the European Society for Medical Oncology. Abstract
Othus M, Estey E, Gale RP.  2016.  Assessment of Minimal Residual Disease in Standard-Risk AML.. The New England journal of medicine. 375(6):e9.
Achille NJ, Othus M, Phelan K, Zhang S, Cooper K, Godwin JE, Appelbaum FR, Radich JP, Erba HP, Nand S et al..  2016.  Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.. Leukemia research. Abstract
Bar M, Tong W, Othus M, Loeb KR, Estey EH.  2015.  Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(3):546-51. Abstract
Othus M, Li Y, Tiwari R.  2012.  Change point-cure models with application to estimating the change-point effect of age of diagnosis among prostate cancer patients.. Journal of applied statistics. 39(4):901-911. Abstract
Wu D, Anderson MM, Othus M, Wood BL.  2016.  Clinical Experience With Modified, Single-Tube T-Cell Receptor Vβ Flow Cytometry Analysis for T-Cell Clonality.. American journal of clinical pathology. 145(4):467-85. Abstract
Othus M, Barlogie B, Leblanc ML, Crowley JJ.  2012.  Cure Models as a Useful Statistical Tool for Analyzing Survival.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(14):3731-3736. Abstract
Chen TL, Estey EH, Othus M, Gardner KM, Markle LJ, Walter RB.  2013.  Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.. Leukemia & lymphoma.
Medeiros BC, Othus M, Appelbaum FR.  2011.  Cytarabine dose for acute myeloid leukemia.. The New England journal of medicine. 364(22):2167-8;authorreply2168-9.
Medeiros BC, Othus M, Fang M, Appelbaum FR, Erba HP.  2015.  Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.. Haematologica. 100(3):331-5. Abstract
Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR et al..  2014.  Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.. Leukemia. 28(2):289-92. Abstract
Mantha S, Goldman DA, Devlin SM, Lee J-W, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM et al..  2017.  Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.. Blood. Abstract
Araki D, Othus M, Walter RB, Becker PS, Sandhu V, Estey EH.  2015.  Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy? Leukemia & lymphoma. :1-3.
Araki D, Othus M, Walter RB, Sandhu V, Sandmaier BM, Becker PS, Appelbaum FR, Estey EH.  2015.  Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.. Haematologica. 100(7):e254-6.
Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee J-W, Sun Z, Tallman MS, Patel J, Gönen M et al..  2015.  Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.. Leukemia.
Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, Erba HP, Walter RB.  2016.  Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.. Leukemia.
Bar M, Othus M, Park HM, Sandhu V, Chen X, Wood BL, Estey E.  2015.  Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.. Leukemia & lymphoma. 56(11):3109-3115. Abstract
Walter RB, Othus M, Löwenberg B, Ossenkoppele GJ, Petersdorf SH, Pabst T, Vekemans M-C, Appelbaum FR, Erba HP, Estey EH.  2015.  Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory Acute Myeloid Leukemia: Analysis of 1,892 Patients from HOVON/SAKK and SWOG.. Haematologica. 100(10):e409-e411.
Othus M, Appelbaum FR, Petersdorf SH, Kopecky KJ, Slovak M, Nevill T, Brandwein J, Larson RA, Stiff PJ, Walter RB et al..  2015.  Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(3):559-64. Abstract
Chen X, Othus M, Wood BL, Walter RB, Percival M-EM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH.  2017.  Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.. Leukemia & lymphoma. :1-3.